Ontada’s Post

I just discovered an insightful publication in Cancer Medicine on the crucial role of communication in precision oncology between patients and healthcare professionals. It's a compelling dive into the challenges and best practices that can truly make a difference in patient care. It is highly recommended for anyone involved in healthcare to check it out and contribute to the ongoing discussion for better patient outcomes.   🔗 https://lnkd.in/dg5xtRKa #PrecisionOncology #PatientCare #HealthcareCommunication

Last month, Avestria led Clarified Precision Medicine's Seed round. This month, we're telling you why we invested in Clarified in the first place. This new "Under the Microscope" blog post from Avestria's Eva Epker covers the advantages of genomically-informed precision oncology treatments, the current challenges patients face in receiving those treatments, and the way that Clarified can help fill those gaps. Read more about why we invested in Clarified right here: https://lnkd.in/gZMEgKQn April Lynch Rajni Natesan, MD, MBA #healthcare #investment #precisiononcology #precisionmedicine #oncology #genomictesting

Revolutionizing cancer research with external control arms (ECAs)! 🚀 In a recent scoping review conducted by our team, we highlight some of the benefits of ECAs and why they are a game-changer! 🌟 ✅ Reduced burden: ECAs minimize the ethical and logistical challenges of assigning patients to placebo or control groups. ✅ Accelerated timelines: By utilizing existing data, ECAs can significantly speed up research. ✅ Cost-effectiveness: Leveraging existing data sources reduces the costs associated with recruitment and follow-up. ✅ Enhanced precision: ECAs can be tailored to match the characteristics of treatment groups, ensuring more accurate comparisons. ✅ Use of real-world data: ECAs incorporate data from real-world settings, offering insights that are highly relevant to clinical practice. ✅ Improved feasibility: ECAs are particularly beneficial for evaluating rare diseases or targeted therapies in precision oncology, where patient populations are often limited and highly specific. #rwd #rwe #realworlddata #realworldevidence #cancer #oncology #research #data #bigdata #analytics #advancedanalytics #cancercare #externalcontrolarm #externalcontrolarms Oncology Outcomes (O2) Inka Health

Another article on the need for reform in coverage for biomarker testing and imaging to improve access to the benefits for precision medicine in cancer and other diseases. #precisionmedicine #oncology #biomarkertesting

In Clinical Lung Cancer, Arthi Sridhar Eric Singhi H. Jack West provide Insights into mNSCLC Management through a Global Clinician Survey 📅 Conducted between July and August 2023, they engaged 127 healthcare professionals from prominent academic systems, primarily within the US. ➡️ Findings show a strong preference for NGS in non-squamous mNSCLC (93%), though its use in squamous cell types is less frequent (54%). Challenges such as insufficient tissue samples, infrastructural limitations, and reimbursement issues are notable obstacles. 🧬 With 72% of clinicians awaiting NGS results before initiating treatment, the importance of timely and accurate testing is clear. However, less than half of the respondents routinely refer mNSCLC patients for clinical trials, underscoring a gap in harnessing cutting-edge therapies from the outset. 🏥 As we move forward, it's imperative to address these barriers to ensure every patient with mNSCLC can benefit from the most informed, effective treatment strategies. 👉 Full paper: https://lnkd.in/ggXpKDbp #mNSCLC #Oncology #NGS #ClinicalTrials #PatientCare

The landscape of cancer treatments is dynamic, requiring Navigators to stay informed and pursue continuous learning to effectively advocate for patients. By staying abreast of molecular profiling advancements and the latest clinical trials, Navigators ensure personalized, innovative treatment options for patients throughout their cancer journey. Serving as a vital link, Navigators connect patients to cutting-edge research and innovative therapies that offer hope and new possibilities where current cures fall short. Read more in part 3/5 of our Clinical Trial Catalyst series on the Navigator’s Role in Understanding Molecular Profiling and Locating/Identifying Clinical Trials: https://lnkd.in/etJafhmZ AONN+ #CancerTreatment #PatientCare #ClinicalTrials

I’m thrilled to announce the publication of our meta-analysis in the “American Journal of Clinical Oncology.” This work examines the role of targeted therapies in oncology, offering a comprehensive look at how precision medicine is shaping treatment outcomes. It’s been a rewarding experience collaborating with an exceptional team, and I’m excited about the future of research in this field. Grateful for the support along the way! You can explore the article here: [https://lnkd.in/gKFmuYYE] #OncologyResearch #TargetedTherapies #PrecisionMedicine #ClinicalOutcomes

2023 Precision Medicine survey findings suggest that the top healthcare institutions in the US are continuing to invest in capabilities for delivering precision oncology to patients. The survey revealed that investments in clinical decision support and new hires with expertise in precision oncology or molecular diagnostics were made by seven respondents. Additionally, six indicated their institutions had hired support staff like nurse navigators who could enable precision oncology. The survey also found that eight institutions invested in internal or external molecular tumor boards that review patients' molecular test results and provide guidance on treatment strategies. #precisionmedicine #oncology

Today I have the opportunity to share my experience matching patients to clinical trial using Deep 6 AI. I proudly built my first study and got pretty accurate matches without having to refine the initial build. #clinicalTrials #DiversityInClinicalTrials

Recruiting for oncology trials can be difficult due to complex criteria, difficulty tracking disease progression, and trying to identify specific genetic profiles. We'll be at #ASCO24 discussing how Deep 6 AI helps solve for these issues with a comprehensive next-generation patient matching solution used by top NCI-designated cancer centers. Read the blog to learn more about how AI helps accelerate oncology clinical trial recruitment: https://lnkd.in/eNFzV2cP #oncologytrialrecruitment #clinicaltrials #cancertrials #clinicalresearch